🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 5 of 55

  1. Abiraterone acetate

    United Therapeutics Europe Ltd

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  2. Abraxane

    Duke University

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  3. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN, VALPROIC ACID, SIMVASTATIN, CAPECITABINE, VALPROIC ACID, GEMCITABINE

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  4. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  5. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  7. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  8. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  9. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  10. Acalabrutinib

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  11. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  12. Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  13. Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, Tora-Dol 30 mg/ml soluzione iniettabile

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 2 small molecule active

    1 trial

  14. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Pediatric Brain Tumor

    phase 2 mab terminated

    1 trial

  15. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 mab terminated

    1 trial

  16. Ad-RTS-hIL-12 and Veledimex

    Alaunos Therapeutics

    Breast Cancer Nos Metastatic Recurrent

    phase 2 gene therapy terminated

    1 trial

  17. Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

  18. Adebellizumab

    The First People's Hospital of Lianyungang

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  20. Adebrelimab (PD-L1 inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer Metastatic

    phase 2 small molecule active

    1 trial

  21. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  22. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  23. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  24. Administration of experimental treatment association (sotorasib, panitumumab 5FU)

    NORTHWEST BIOTHERAPEUTICS INC

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  25. Aerobic exercise training

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 other completed

    1 trial

  26. Afatinib and Paclitaxel

    United Therapeutics Europe Ltd

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  27. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  28. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  29. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  30. Aglatimagene besadenovec

    Candel Therapeutics

    Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  31. Aglatimagene besadenovec

    Candel Therapeutics

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 mab active

    1 trial

  32. Albumin Paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  33. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial

  34. Alectinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bone Cancer

    phase 2 small molecule active

    1 trial

  35. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  36. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

  37. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  38. Alisertib

    Takeda

    Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  39. Alisertib

    Takeda

    Ovarian Carcinoma

    phase 2 small molecule completed

    2 trials

  40. Alisertib

    Takeda

    Adenocarcinoma of the Prostate

    phase 2 small molecule completed

    1 trial

  41. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  42. Alisertib

    Takeda

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  43. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  44. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Alisertib

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  46. Alisertib (MLN8237)

    Takeda

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  47. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  48. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.